Use of a compound having the structure of formula A1 for the preparation of a medicament for treating an ocular disease, particularly a diabetes related ocular disease in a subject, wherein the ocular disease is selected from the group consisting of proliferative vitreoretinopathy (PVR), uveitis, glaucoma and age related macular degeneration (AMD), and the diabetes related ocular disease is selected from the group consisting of diabetic retinopathy (DR) and diabetic macular edema (DME).
